Core Viewpoint - OSE Immunotherapeutics, Inserm Transfert, and Nantes University have formed a strategic partnership to accelerate innovation in immunotherapy, focusing on oncology, inflammation, and autoimmunity [1][2]. Group 1: Partnership Objectives - The partnership aims to combine academic research with industrial expertise to transform immunology discoveries into industrial programs that can deliver breakthrough therapies to patients [2]. - The collaboration will unite scientific teams and pool expertise to develop innovative projects into programs ready for industrial development [3]. Group 2: Project Development - Inserm Transfert and Nantes University will lead the project identification process, allowing OSE Immunotherapeutics to access promising programs from their research units [3]. - Selected projects will receive financial support and dedicated guidance to facilitate their development [3]. Group 3: Leadership Insights - Pascale Augé from Inserm Transfert emphasized the importance of public-private partnerships in healthcare and the commitment to supporting research excellence [4]. - Frédéric Jacquemin from Nantes University highlighted the role of collaborative research in driving therapeutic innovation [4]. - Nicolas Poirier from OSE Immunotherapeutics expressed enthusiasm for the collaboration, noting its potential to enhance immunological innovation across France [4]. Group 4: Organizational Background - Inserm Transfert is a private subsidiary of Inserm focused on development and innovation in human health, managing the entire innovation value chain from research to industry [5]. - Nantes University is recognized for its excellence in health research and innovation, contributing to the collaborative research and technology transfer efforts [6][7]. - OSE Immunotherapeutics specializes in developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with academic institutions and biopharmaceutical companies [8].

Core Viewpoint - OSE Immunotherapeutics reports a significant decrease in cash position as of June 30, 2025, and anticipates funding operations until Q4 2026, while exploring options to extend its financial runway [4][5][6]. Financial Position - As of June 30, 2025, OSE Immunotherapeutics' cash position totaled €41.6 million, down from €64.2 million as of December 31, 2024 [4]. - The cash position includes €25.4 million in cash and cash equivalents, and €16.2 million in fixed-term deposits classified as current and non-current financial assets [4]. Funding Outlook - The company believes its operations are funded until the beginning of Q4 2026, factoring in the potential exercise of remaining warrants issued to Vester Finance, but excluding any upcoming milestone payments from current partnerships [5]. - If anticipated milestones are received in 2026, the cash runway could extend to at least Q1 2027 [5]. Strategic Initiatives - To extend its financial runway beyond 2026, the company is evaluating several options, including potential new strategic partnerships, equity financing, restructuring existing debt, and possible milestone payments from current partnerships [6]. Partnership Update - The company has updated its expectations regarding the AbbVie partnership related to ABBV-230, indicating a delay in the initiation of the Phase 1 trial and the associated milestone payment [3].

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court NANTES, France – September 23, 2025, 10:30 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) acknowledges the decision rendered on September 23, 2025, by the Nantes Commercial Court rejecting its claims in the proceedings concerning the declaration of concerted action by a group of minority shareholders. In the best interests of the Company, in order to focus on the execution of its strategy and to allow the ...

Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that two international proxy advisory firms, including Glass Lewis, recommend shareholders to vote IN FAVOR of the resolutions proposed by the Board of Directors regarding its composition (resolutions 5 to 8) at the general meeting of shareholders ...

Core Points - A shareholders' agreement has been executed by 61 founding, historical, employee, and executive shareholders of OSE Immunotherapeutics, representing approximately 20.1% of voting rights, concerning the vote on resolutions for the Board of Directors at the general meeting scheduled for September 30, 2025 [1][2]. Group 1: Shareholders' Agreement - The Shareholders' Group holds approximately 15.7% of the share capital and approximately 20.1% of the voting rights of the Company [2]. - The Shareholders' Group has committed to vote in favor of the Board of Directors' proposed resolutions regarding its own composition and against the resolutions proposed by minority shareholders [3]. Group 2: General Meeting Participation - Shareholders can participate in the General Meeting either in person, by mail, online via VOTACCESS, or by granting proxy to the Chairman or another person of their choice [4][8]. - For any proxy granted without naming a proxyholder, the Chairman will vote in favor of the Board's resolutions and against all other resolutions [4]. Group 3: Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with leading academic institutions and biopharmaceutical companies [6].

Core Viewpoint - OSE Immunotherapeutics and the FoRT Foundation have completed patient enrollment in the Combi-TED Phase 2 clinical trial, which evaluates the therapeutic cancer vaccine Tedopi® in combination with nivolumab or docetaxel for patients with Non-Small Cell Lung Cancer (NSCLC) [1][4][8] Group 1: Clinical Trial Details - The Combi-TED trial is an open-label, randomized, three-arm Phase 2 study involving 105 HLA-A2 positive patients with metastatic NSCLC who have not shown evidence of EGFR mutations or ALK or ROS1 rearrangement after first-line treatment [3][8] - The primary endpoint of the trial is the 1-year survival rate, with results expected in the second half of 2026 [3][8] - The trial is sponsored by the FoRT Foundation and conducted across sites in Italy, France, and Spain [2] Group 2: Expert Commentary - Dr. Federico Cappuzzo, Chief Investigator, expressed optimism about the trial's completion, highlighting the potential of Tedopi® to enhance the effectiveness of checkpoint inhibitors or chemotherapy [4] - Silvia Comis, Chief Clinical and Medical Research Officer, noted that the trial represents a significant step in evaluating innovative second-line treatment combinations for NSCLC [5] Group 3: Company Background - OSE Immunotherapeutics is focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, aiming to address unmet patient needs [6] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [6]

Core Insights - OSE Immunotherapeutics is committed to value creation through innovative therapies in immuno-oncology and immuno-inflammation, supported by a strong portfolio and balanced governance [1][3][6] Strategic Focus - The company aims to achieve significant clinical milestones in 2026, 2027, and 2028 for its two flagship programs, leveraging differentiated assets with robust clinical data [2][3] - Development plans include Phase 2b for Lusvertikimab and Phase 3 for Tedopi®, with an emphasis on maintaining momentum and engaging strategic partners [3][5] Governance and Shareholder Dynamics - A minority shareholder group proposes a return to a previous model focused on a single asset, Tedopi®, which the company views as risky and lacking a clear strategy for Lusvertikimab [4][6][7] - The company emphasizes the importance of its current governance structure and the risks associated with a complete board overhaul proposed by minority shareholders [7][8][9] Financial and Operational Outlook - The company is focused on ensuring business continuity and financing for Tedopi®'s Phase 3 trial while continuing the development of Lusvertikimab [5][13] - The current trajectory is aligned with industry standards and aims to preserve and maximize shareholder value through a balanced pipeline of assets [6][13]

Core Viewpoint - OSE Immunotherapeutics is reaffirming its strategic priorities and addressing shareholder concerns ahead of its Annual General Meeting (AGM) scheduled for September 30, 2025, amidst shareholder activism and misinformation campaigns [1][3][4] Company Strategy - The company aims to leverage its two main programs, Tedopi® and Lusvertikimab, through strategic partnerships and financing, positioning itself as a leading European biotech in immunotherapy for oncology and inflammation [2][5] - OSE's strategy focuses on maintaining strategic optionality for its lead assets while balancing near-term financing and value creation to avoid premature dilution of shareholder value [5][6] Shareholder Activism - OSE has faced significant shareholder activism, including a misinformation campaign by minority shareholders, which has created confusion ahead of the AGM [3][8] - The company has initiated legal actions to protect all shareholders and ensure a fair debate, as the activist group has allegedly acted against sound governance principles [8][10] AGM and Legal Proceedings - The AGM has been postponed to September 30, 2025, to ensure fair voting conditions based on accurate information regarding the intentions of the activist shareholders [9][11] - Legal proceedings have been initiated to investigate the actions of minority shareholders, with potential implications for their voting rights if irregularities are confirmed [10][11] Financial and Development Plans - Tedopi® is in a pivotal Phase 3 clinical trial for non-small cell lung cancer, with enrollment completion expected in the second half of 2026 and initial readouts anticipated by the end of 2027 [14] - Lusvertikimab's development includes a Phase 2b trial in ulcerative colitis, expected to start in 2026, with readouts in 2027 and 2028 [14] - The company has clarified that the expected cost for the Lusvertikimab trial is in the tens of millions of euros, significantly lower than misleading figures circulated by activist shareholders [14] Governance and Communication - OSE emphasizes its commitment to transparent governance and has published a Shareholder Q&A to counter misinformation and provide clear information on its strategy and financial trajectory [7][12] - The company is dedicated to maintaining open dialogue with shareholders and encourages them to review the Q&A document for accurate information [13]

Core Viewpoint - OSE Immunotherapeutics is evolving its governance structure to enhance shareholder representation and align with strategic priorities ahead of its Annual General Meeting scheduled for September 30, 2025 [2][4]. Governance Evolution - The new governance framework aims to ensure balanced representation, featuring a Board structure with two current independent members, two new independent directors, two seats for concertist shareholders (representing 20% of equity), one for the CEO, and one for employee shareholders [4][5]. - This restructuring is intended to reflect the diversity of the shareholder base and prepare the company for future strategic opportunities and challenges [4][5]. Strategic Focus - The company remains committed to maximizing the potential of its key therapeutic assets, Tedopi® and Lusvertikimab, through strategic partnerships and financing [5][6]. - OSE Immunotherapeutics is actively pursuing business development partnerships and financing opportunities to ensure both programs are adequately resourced [5][6]. Clinical Development Plans - The company is advancing Tedopi® into a pivotal phase 3 study for lung cancer, with plans to complete enrollment next year [6][7]. - Lusvertikimab will enter a focused phase 2b study to determine optimal dosing and validate its formulation, reflecting feedback from potential partners [6][7]. Annual General Meeting Details - The Annual General Meeting will take place on September 30, 2025, at 10:00 a.m. CET, with electronic voting available for shareholders [8][9]. - A shareholder webinar is scheduled for September 18, 2025, to present key updates and engage with shareholders [10].

Core Insights - OSE Immunotherapeutics has appointed Thomas Gidoin as Chief Financial Officer, bringing over 15 years of international expertise in capital markets and financial strategy [1][5][6] - Gidoin has a strong background in biopharma finance, having previously served as CFO at Advesya and GenSight Biologics, where he led financing strategies from Series B to IPO [2][3] - The company is positioned for growth with two late-stage assets in oncology and inflammation, supported by an innovative research platform [6][7] Company Overview - OSE Immunotherapeutics is focused on developing first-in-class assets in immuno-oncology and immuno-inflammation to address unmet patient needs [7] - The company collaborates with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [7] - OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext [7]